| abstract |
The invention relates to n-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (sGC) for the treatment of cardiovascular diseases, such as for example heart insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischaemia, vascular diseases, renal insufficiency, thromboembolic diseases, fibrotic diseases, arteriosclerosis, dementia diseases and erectile dysfunction. |